After quitting my job, I decided to study for a Master’s degree in Nutritional Therapy. As I got deeper into my course work,I was shocked to discover that everything I had learned during my undergraduate studies was either false, misleading, or outdated information.
It’s an anecdote, but a pretty powerful one. The ignorance about nutrition in the health-care field is probably killing thousands.
A daily habit may contribute to longevity.
That’s why I choke down the swill ever morning. I’ve never found any other reasons to do so.
Speaking of my apparent imperviousness to caffeine, I was staying with an old (in both senses of the word) friend in Seattle last week, and he noted that since he’d gone more paleo in his diet, he noticed much less of a caffeine effect from morning coffee or evening tea. I started drinking it after I’d changed my diet as well, so maybe carbs enhance it. Actually, someone should do a study on that.
This is truly bizarre. I don’t think I’ll try it with Rerun, though, even though I happened to buy a cucumber the other day. She gets enough abuse.
Kim Stanley Robinson says they’re impossible.
I call Clarke’s Law about distinguished scientists, even though he’s just a fiction writer.
Google is committing $50M to conquering it. Considering how much it costs (as the article points out), this is chump change.
Is it time to end it?
Yes. It’s as worse-than-worthless as the climate models, in that it provides far too many false positives. And as we saw with Climategate, it’s too easy for it to become “pal review.”
Thoughts from Bob Zimmerman on the tremendous uncertainty.
The models are worse than worthless as a guide to policy.
How he went from climate promoter to climate skeptic.
It’s amazing how pathetic the warm mongers’ “arguments” are. It’s one of the ways you can tell it’s not science; it’s ideology and religion.
[Update a while later]
Bjorn Lomborg on the trivial effects of current climate proposals. But the economic impacts would be far from trivial.
…seems to have general rejuvenating effects on mice.
And human trials start next year.
Paul Ehrlich, on Mark Steyn’s latest.